Physician profile
Jonathan Dychko
NPI 1063972420
$474.45
in general payments reported to CMS, 2019-2025
14 companies · $329 in 2025
The $329 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $71.64 · 2022: $22.31 · 2023: $37.00 · 2024: $14.13 · 2025: $329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $380.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $84.59 | 2025 | |
| Amgen INC. | $51.94 | 2023-2025 | Repatha, Evenity, Otezla |
| Otsuka America Pharmaceutical, INC. | $43.16 | 2025 | Rexulti |
| Novo Nordisk INC | $41.70 | 2025 | Ozempic, Rybelsus |
| Vanda Pharmaceuticals INC. | $39.32 | 2022-2023 | Hetlioz |
| Lilly USA, LLC | $33.92 | 2025 | Zepbound, Mounjaro, Kisunla |
| Teva Pharmaceuticals USA, INC. | $33.73 | 2025 | Austedo Xr |
| Abbvie INC. | $25.63 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $23.24 | 2020 | |
| Octapharma USA, INC. | $22.77 | 2020 | |
| Glaxosmithkline, LLC. | $20.32 | 2025 | Trelegy Ellipta |
| Heartflow, INC. | $20.32 | 2025 | |
| Aimmune Therapeutics, INC. | $18.20 | 2025 | Zenpep |
| Sumitomo Pharma America, INC. | $15.61 | 2025 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Dychko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.